While the role of CD36 in this setting remains unclear, the level of CD36 cell surface expression remained stable in MAPK inhibitor-resistant cells and offers the possibility to serve as a potential biomarker for this drug resistant population in melanoma. Here, CD36 is linked to melanoma.